Literature DB >> 17692440

Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs.

Maryam Amidi1, Hubert C Pellikaan, Hoang Hirschberg, Anne H de Boer, Daan J A Crommelin, Wim E Hennink, Gideon Kersten, Wim Jiskoot.   

Abstract

In this study, the potential of N-Trimethyl chitosan (TMC, degree of quaternization 50%) and dextran microparticles for pulmonary delivery of diphtheria toxoid (DT) was investigated. The antigen-containing microparticles were prepared by drying of an aqueous solution of polymer and DT through a supercritical fluid (SCF) spraying process. The median volume diameter of the dry particles, as determined by laser diffraction analysis, was between 2 and 3 microm and the fine particle mass fractions smaller than 5 microm, as determined by cascade impactor analysis, were 35 and 56% for the dextran and TMC formulations, respectively. The water content of the particles as measured by Karl-Fischer titration was 2-3% (w/w). Pulmonary immunization with DT-TMC microparticles containing 2 or 10 Lf of DT resulted in a strong immunological response as reflected by the induction of IgM, IgG, IgG subclasses (IgG1 and IgG2) antibodies as well as neutralizing antibody titers comparable to or significantly higher than those achieved after subcutaneous (SC) administration of alum-adsorbed DT (2 Lf). Moreover, the IgG2/IgG1 ratio after pulmonary immunization with DT-TMC microparticles was substantially higher as compared to SC administered alum-adsorbed DT. In contrast, pulmonarily administered DT-dextran particles were poorly immunogenic. Among the tested formulations only pulmonarily administered DT-containing TMC microparticles induced detectable pulmonary secretory IgA levels. In conclusion, in this paper it is demonstrated that TMC microparticles are a potent new delivery system for pulmonary administered DT antigen.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17692440     DOI: 10.1016/j.vaccine.2007.05.064

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses.

Authors:  Pavan Muttil; Brian Pulliam; Lucila Garcia-Contreras; John Kevin Fallon; Chenchen Wang; Anthony James Hickey; David A Edwards
Journal:  AAPS J       Date:  2010-09-28       Impact factor: 4.009

Review 2.  Nanocarriers targeting dendritic cells for pulmonary vaccine delivery.

Authors:  Nitesh K Kunda; Satyanarayana Somavarapu; Stephen B Gordon; Gillian A Hutcheon; Imran Y Saleem
Journal:  Pharm Res       Date:  2012-10-09       Impact factor: 4.200

3.  Particle size influences the immune response produced by hepatitis B vaccine formulated in inhalable particles.

Authors:  Chandan Thomas; Vivek Gupta; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2010-03-16       Impact factor: 4.200

4.  Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route.

Authors:  Pavan Muttil; Cecilia Prego; Lucila Garcia-Contreras; Brian Pulliam; John Kevin Fallon; Chenchen Wang; Anthony James Hickey; David Edwards
Journal:  AAPS J       Date:  2010-04-24       Impact factor: 4.009

5.  Microneedle-based transcutaneous immunisation in mice with N-trimethyl chitosan adjuvanted diphtheria toxoid formulations.

Authors:  Suzanne M Bal; Zhi Ding; Gideon F A Kersten; Wim Jiskoot; Joke A Bouwstra
Journal:  Pharm Res       Date:  2010-06-18       Impact factor: 4.200

Review 6.  Vaccine adjuvants: current challenges and future approaches.

Authors:  Jennifer H Wilson-Welder; Maria P Torres; Matt J Kipper; Surya K Mallapragada; Michael J Wannemuehler; Balaji Narasimhan
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

Review 7.  Development of stable influenza vaccine powder formulations: challenges and possibilities.

Authors:  J-P Amorij; A Huckriede; J Wilschut; H W Frijlink; W L J Hinrichs
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

8.  Physicochemical and immunological characterization of N,N,N-trimethyl chitosan-coated whole inactivated influenza virus vaccine for intranasal administration.

Authors:  Niels Hagenaars; Enrico Mastrobattista; Rolf J Verheul; Imke Mooren; Harrie L Glansbeek; Jacco G M Heldens; Han van den Bosch; Wim Jiskoot
Journal:  Pharm Res       Date:  2009-02-18       Impact factor: 4.200

Review 9.  Trimethyl chitosan and its applications in drug delivery.

Authors:  V K Mourya; Nazma N Inamdar
Journal:  J Mater Sci Mater Med       Date:  2008-12-27       Impact factor: 3.896

Review 10.  Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines?

Authors:  Sharan Bobbala; Sarah Hook
Journal:  Pharm Res       Date:  2016-07-05       Impact factor: 4.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.